UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 12, 2021, The Cooper Companies, Inc. (the “Company”) announced that, on recommendation of the Corporate Governance & Nominating Committee, the Board of Directors of the Company (the “Board”) voted to expand the size of the Board from 7 directors to 8 directors with effect from July 1, 2021 and to elect Maria Rivas, MD to fill the new director position, with effect from July 1, 2021, until her successor is duly elected and qualified or her earlier resignation or removal. Dr. Rivas has been determined to be an independent director under New York Stock Exchange listing standards. There are no arrangements or understandings between Dr. Rivas and any other persons pursuant to which she was selected as a director. Additionally, there are no transactions involving the Company and Dr. Rivas that the Company would be required to report pursuant to Item 404(a) of Regulation S-K. Dr. Rivas will be compensated for her service as a director consistent with the compensation provided to other non-employee directors as described in the Company’s most recent proxy statement, filed with the Securities and Exchange Commission on January 29, 2021.
Item 7.01. Regulation FD Disclosure.
A copy of the press release announcing the appointment of Dr. Rivas is attached hereto as Exhibit 99.1. Internet addresses in the release are for information purposes only and are not intended to be hyperlinks to other information of the Company.
The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, will not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press Release dated May 12, 2021. | |
| 104.1 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| THE COOPER COMPANIES, INC. | ||
| By: | /s/ Mark J. Drury | |
| Mark J. Drury | ||
| Vice President, General Counsel & Secretary | ||
Dated: May 12, 2021
Exhibit 99.1
PRESS RELEASE
CooperCompanies Elects Maria Rivas, MD to Board of Directors
SAN RAMON, Calif., May 12, 2021 — CooperCompanies (NYSE: COO) announced today that its Board of Directors has elected Dr. Maria Rivas as an independent director, effective July 1, 2021.
“We are pleased to welcome Maria to our Board of Directors,” said Al White, President and CEO. “Maria brings a very valuable perspective with her background in fertility, medical affairs, product development, and global regulatory. We look forward to her advice and contributions as CooperCompanies continues to grow.”
Dr. Rivas currently serves as Chief Medical Officer and Senior Vice President for the healthcare business of Merck KGaA, Darmstadt, Germany (which operates as EMD Serono in the US and Canada) where she leads the Global Pharmacovigilance, Medical Affairs and Evidence and Value Development (HEOR) teams in over 90 countries.
Prior to that, Dr. Rivas served as Senior Vice President of Global Medical Affairs at Merck & Co (MSD), as Vice President of Global Medical Affairs at Abbvie, as Vice President of Oncology, General Medicine and Diagnostic Imaging Medical Affairs at Bayer Healthcare, and in various roles at Eli Lilly including Head of US Women’s Health Medical Affairs. Before joining Eli Lilly, Dr. Rivas was in private practice as an endocrinologist in Puerto Rico.
Born in Cuba, Dr. Rivas grew up in Puerto Rico and still has many family, friends and professional connections there. In 2020, she was named among the Top 100 Most Influential Latinas by Latino Leaders Magazine.
Cooper’s Board of Directors has welcomed several new directors and leaders in recent months. In November 2020, Teresa S. Madden was elected to the Board as an independent director. In March, Robert S. Weiss was elected Chairman of the Board, and William A. Kozy was elected Vice Chairman and Lead Director replacing A. Thomas Bender and Allan E. Rubenstein, M.D., respectively, who retired after many years of service.
With the addition of Dr. Rivas, the Board will be comprised of eight directors, six of whom are independent. Cooper’s Board members are:
| 1. | Robert S. Weiss, Chairman of the Board |
| 2. | William (Bill) A. Kozy, Vice Chairman and Lead Director |
| 3. | Colleen E. Jay, Director |
| 4. | Jody S. Lindell, Director |
| 5. | Teresa S. Madden, Director |
| 6. | Gary S. Petersmeyer, Director |
| 7. | Dr. Maria Rivas, Director (effective July 1, 2021) |
| 8. | Albert G. White III, President & Chief Executive Officer, CooperCompanies |
About CooperCompanies
CooperCompanies (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com